CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC) ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association Fractional Flow Reserve-Guided Complete Revascularization Improves the Prognosis in Patients With ST-Segment-Elevation Myocardial Infarction and Severe Nonculprit Disease: A DANAMI 3-PRIMULTI Substudy (Primary PCI in Patients With ST-Elevation Myocardial Infarction and Multivessel Disease: Treatment Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function 2-Year Outcomes After Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients 中国肺动脉高压诊断与治疗指南(2021版) Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombosis and Cerebral Thromboembolism after TAVR: The ADAPT-TAVR Randomized Clinical Trial Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study Minimum Core Data Elements for Evaluation of TAVR: A Scientific Statement by PASSION CV, HVC, and TVT Registry

Original Research

JOURNAL:CBSMD Article Link

TAVR后的冠状动脉介入

CBSMD

Pre-reading


接受经导管主动脉瓣置换术(TAVR)治疗的患者的冠状动脉事件的累积风险较高,冠状动脉通路是否良好对于后续的冠脉介入是个挑战,最新一期的JACC Intervention为TAVR及后续的冠脉介入特刊


1. “Coronary Access After TAVR” 介绍了真实世界中通过CT明确的TAVR术后冠状动脉通路不良(unfavorable coronary access)患者的冠脉介入成功率数据后发现:

1)TAVR术后冠脉通路不良患者的冠脉介入成功率低于冠状动脉通路良好的患者。Evolut R/Evolut PRO 组(0.0% vs. 77.8%; p = 0.003),SAPIEN 3 组(33.3% vs. 91.4%; p = 0.003) ;

2)提出了TAVR术中有助于保持良好冠状动脉通路的技术细节。


2. “Coronary Access After TAVR With a Self-Expanding Bioprosthesis: Insights From Computed Tomography”介绍了通过多层计算机断层CT观察到的经导管心脏瓣膜(THV)中位TAVR 30天后与左、右冠脉开口的相对解剖位置。



3. Low Risk TAVR试验 "Feasibility of Coronary Access and Aortic Valve Reintervention in Low-Risk TAVR Patients"指出TAVR治疗会对低风险患者的冠状通路造成影响, 或引发主动脉瓣再干预(TAVR-in-TAVR)时的冠脉阻塞。



4. “Coronary Protection to Prevent Coronary Obstruction During TAVR:A Multicenter International Registry”则比较了TAVR术后冠脉保护的两种方案,3年随访结果显示:

1) 通过支架保护冠脉开口后的心源性死亡率显著低于导丝保护后的心源性死亡率(7.8% vs. 15.8%, adjusted hazard ratio: 0.42; 95% confidence interval: 0.14 to 1.28; p = 0.13;且通过置入支架保护的TAVR患者的明确的支架内血栓发生率不高(0.9%);

2)通过导丝保护冠脉开口的患者需要预防延迟性的冠脉闭塞(delayed coronary occlusions),发生率为4.3%。